{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tarlatamab"]],"indication":"de novo or treatment emergent neuroendocrine prostate cancer","name":"DeLLpro-300","nct_id":"NCT04702737","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellpro-300-nct04702737. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DeLLpro-300","arms":[{"description":"The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.","label":"Part 1: Dose Exploration","type":"EXPERIMENTAL"},{"description":"Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-07-22","type":"ACTUAL"},"conditions":["Neuroendocrine Prostate Cancer"],"enrollment":{"count":41,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tarlatamab","otherNames":["AMG 757"],"type":"DRUG"}],"last_update":"2025-09-12","lead_sponsor":"Amgen","official_title":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2024-07-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 28 days"}],"references":[{"citation":"Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin Cancer Res. 2025 Sep 15;31(18):3854-3863. doi: 10.1158/1078-0432.CCR-25-1211.","pmid":"40689871","type":"DERIVED"}],"start_date":{"date":"2021-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04702737"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellpro-300-nct04702737"}